TEVA ASKS SUPREME COURT NOT TO REVIEW PATENT ISSUE IN BARACLUDE CASE Bristol-Myers Squibb Co. v. Teva Pharms. | Secondary Sources | Westlaw

TEVA ASKS SUPREME COURT NOT TO REVIEW PATENT ISSUE IN BARACLUDE CASE Bristol-Myers Squibb Co. v. Teva Pharms. | Secondary Sources | Westlaw

View on Westlaw or start a FREE TRIAL today, TEVA ASKS SUPREME COURT NOT TO REVIEW PATENT ISSUE IN BARACLUDE CASE Bristol-Myers Squibb Co. v. Teva Pharms., Secondary Sources
Skip Page Header

TEVA ASKS SUPREME COURT NOT TO REVIEW PATENT ISSUE IN BARACLUDE CASE Bristol-Myers Squibb Co. v. Teva Pharms.

31 No. 3 WJPHAR 6By Michael Scott Leonard, Senior Legal Writer, Westlaw JournalsWestlaw Journal Pharmaceutical (Approx. 4 pages)

TEVA ASKS SUPREME COURT NOT TO REVIEW PATENT ISSUE IN BARACLUDE CASE Bristol-Myers Squibb Co. v. Teva Pharms.

31 No. 3 WJPHAR 6By Michael Scott Leonard, Senior Legal Writer, Westlaw JournalsWestlaw Journal Pharmaceutical (Approx. 4 pages)

31 No. 3 Westlaw Journal Pharmaceutical 6
Westlaw Journal Pharmaceutical
*1 April 21, 2015
Baraclude/Entecavir (Patents)
By Michael Scott Leonard, Senior Legal Writer, Westlaw Journals
Copyright © 2015 Thomson Reuters .

TEVA ASKS SUPREME COURT NOT TO REVIEW PATENT ISSUE IN BARACLUDE CASE

Bristol-Myers Squibb Co. v. Teva Pharms.

Briefs and Other Related Documents
Teva Pharmaceuticals is asking the U.S. Supreme Court not to second-guess a lower court ruling invalidating patents on Bristol-Myers Squibb's hepatitis B blockbuster drug Baraclude despite evidence -- discovered years after the drug's rollout -- that...
End of Document© 2024 Thomson Reuters. No claim to original U.S. Government Works.